The QualityStocks Daily Friday, October 30th, 2020

Today's Top 3 Investment Newsletters

Tip.us (SIBE) +184.62%

QualityStocks (TTTPF) +78.75%

MiningNewsWire (ATUMF) +28.57%

The QualityStocks Daily Stock List

AcuityAds Holdings, Inc. (ACUIF)

MicroSmallCap, Small Cap Power, Whale Wisdom, Traders Insights, Simply Wall St, Dividend Investor, TMXmoney, Stockwatch, Investing News, Morningstar, StocksCafe, GuruFocus, Business Insider, Proactive Investors, YCharts, Barchart, Baystreet.ca, Stockhouse, Wallet Investor, FX Empire, ChartMill, Market Screener, Nasdaq, PR Newswire, MarketWatch, InvestorX, OTC Markets, and Seeking Alpha reported previously on AcuityAds Holdings, Inc. (ACUIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AcuityAds Holdings, Inc. is a technology leader that provides targeted digital media solutions. These solutions enable advertisers to connect intelligently with audiences across digital advertising campaigns. The Company provides premier audience insights for video, display, native, audio, and connected devices, automating the process and ensuring transparency so a business can confidently capture attention and create one-to-one customer conversations. AcuityAds Holdings is based in Toronto, Ontario. The Company also has offices across the U.S., Europe, and Latin America. AcuityAds Holdings lists on the OTC Markets Group’s OTCQX.

In essence, AcuityAds provides marketers a strong and holistic solution for digital advertising across all advertising formats and screens to increase reach and Share of Attention® throughout the customer journey. Through its inventive, data-driven insights, real-time analytics, and industry-leading activation platform based on proprietary Artificial Intelligence (AI) technology, it leverages an integrated ecosystem of partners for data, inventory, brand safety, and fraud prevention.

The Company’s AI-technology enables brands and agencies to extract key signals outside of the obvious, which contribute to the consumer journey from “unaware of a need” all the way through to conversion. Furthermore, the design of its proprietary decision science technology is to harness all publicly available view data for video campaigns and track how the content performs in real-time. Through evaluating the specifics of how users are engaging with a business’s content (and their competition’s) across dozens of major platforms, AcuityAds help brands optimize for their Share of Attention™.

AcuityAds has its Live Audience solution. Live Audience ensures a business is incorporating the most recent and relevant audience insights to achieve improved efficiency and effectiveness with their media dollars. The Company’s decision science technology calls on information from greater than 700 MM profiles using real-time signals, which provide highly predictive characteristics and conversion propensity insights.

At the beginning of October, AcuityAds Holdings revealed the new advertising automation platform, illumin™. The illumin platform is now available to advertisers. It enables planning, buying, as well as omnichannel intelligence in a single platform for seamless visualization and management of the consumer journey. illumin enables advertisers to map their consumer journey playbooks across screens and execute in real-time using programmatic technology.

This week, AcuityAds Holdings announced that Seraj Bharwani, the Company’s Chief Strategy Officer, will be partnering with client Michele Muhammad, Chief Sales and Marketing Officer of DSE Healthcare Solutions, LLC, to participate on a panel at the CMO Brand Digital Summit titled, "Successful Client-Partner Relationships." DSE Healthcare Solutions is a privately held consumer healthcare company with a portfolio of health and wellness brands. The panel will highlight important learnings from the productive partnership between the two companies.

AcuityAds Holdings, Inc. (ACUIF), closed Friday's trading session at $3.40, off by 0.293255%, on 6,293 volume with 17 trades. The average volume for the last 3 months is 38,241 and the stock's 52-week low/high is $0.51910001/$3.75.

aTyr Pharma, Inc. (LIFE)

Streetwise Reports, Stocktwits, Zacks, Investors Observer, Stocknews, DividendMax, InvestorsHub, Barchart, Finviz, BioSpace, ChartMill, Morningstar, MacroTrends, Annual Reports, Stockhouse, iwatchmarkets, Market Chameleon, MarketBeat, Nasdaq, MarketWatch, Finbox, Simply Wall St, YCharts, Proactive Investors, Seeking Alpha, TMXmoney, Market Screener, Investing.com, GlobeNewswire, Webull, ETF.com, and GuruFocus reported beforehand on aTyr Pharma, Inc. (LIFE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

aTyr Pharma, Inc. engages in the discovery and development of innovative medicines based on novel immunological pathways. A biotherapeutics company, its research and development (R&D) efforts are focused on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company is translating novel biology into first-in-class therapies with improved patient outcomes. aTyr Pharma is based in San Diego, California. The Company lists on the Nasdaq Capital Market (NasdaqCM).

aTyr Pharma has built a global intellectual property (IP) estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. The Company’s primary focus is ATYR1923, a clinical-stage product candidate that binds to the neuropilin-2 receptor. The design of it is to down-regulate immune engagement in inflammatory lung diseases.

The Company is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs). This is a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and have a high unmet medical need. aTyr Pharma selected pulmonary sarcoidosis as its initial ILD indication. It is now enrolling a Phase 1b/2a proof-of-concept multi-center, clinical trial.

In response to the COVID-19 pandemic, aTyr Pharma earlier initiated a Phase 2 study in patients with COVID-19 related severe respiratory complications. The design of the study is to evaluate the safety and preliminary efficacy of ATYR1923 versus placebo through the assessment of key clinical outcome measures. This includes fever and hypoxia and inflammatory biomarkers. In addition, the Company is advancing its pre-clinical pipeline of tRNA synthetases and NRP2 targeting candidates by way of internal research efforts, industry, and academic collaborations.

Earlier this week, aTyr Pharma announced that it completed enrollment in its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in COVID-19 patients with severe respiratory complications. The study enrolled a total of 32 patients at hospitals in the United States and Puerto Rico, surpassing the target enrollment of 30 patients. aTyr expects to report topline data from this trial by the end of this year.

Yesterday, aTyr Pharma announced that it entered into a research collaboration with the Medical University of South Carolina (MUSC). Dr. Robert M. Gemmill, Ph.D., the former Melvyn Berlinksy Chair of Cancer Research and Professor of Medicine Emeritus in the Division of Hematology/Oncology at MUSC, will serve as the principal investigator for the collaboration.

Dr. Gemmill’s research centers on the genetic alteration of genes during lung and kidney cancer development. This includes the role of Neuropilin-2 (NRP2). The collaboration seeks to speed up the development of therapeutic antibodies that selectively target specific NRP2 isoforms and validate their potential use in the treatment of lung cancer.

aTyr Pharma, Inc. (LIFE), closed Friday's trading session at $3.17, off by 3.0581%, on 29,871 volume with 158 trades. The average volume for the last 3 months is 92,553 and the stock's 52-week low/high is $2.13000011/$7.61999988.

GBT Technologies, Inc. (GTCH)

Whale Wisdom, Zacks, Stock Day Media, FX Empire, Financial Buzz, TipRanks, VentureLine, Investing.com, Investors Hangout, Real Investment Advice, Dividend Investor, docoh, Stockhouse, Nasdaq, Investors Observer, OTC Markets, Super Stock Screener, Seeking Alpha, Business Insider, GuruFocus, Wallet Investor, OTC.Watch, Stockwatch, Corporate Information, InvestorsHub, Investor Ideas, Street Insider, Market Screener, GlobeNewswire, OTC Dynamics, Morningstar, Validea, and Simply Wall St reported earlier on GBT Technologies, Inc. (GTCH), and today we report on the Company, here at the QualityStocks Daily Newsletter.

GBT Technologies, Inc. specializes in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies. A development-stage business, it has a portfolio of Intellectual Property (IP) that, upon commercialization, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. GBT Technologies has its Joint Venture (JV), GBT Tokenize Corp. (GBT/Tokenize).

The Company previously went by the name Gopher Protocol, Inc. It changed its name to GBT Technologies, Inc. in August of 2019. Established in 2009, GBT Technologies lists on the OTC Markets.

GBT’s system envisions the establishment of an international mesh network. The core of the system will be its advanced microchip technology, which can undergo installation in any mobile or fixed device worldwide. The Company foresees this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing, and enhanced mobile features as an alternative to traditional carrier services.

GBT Technologies has its GopherInsight™ wireless mesh network technology platform and its Avant! AI, for mobile and fixed solutions. GBTs Core Technology is an innovative platform with products that will change the way people interact with technology and each other.

The Company’s Platform Technology is called the above-mentioned GopherInsight™. It utilizes “public” RF spectrum to facilitate a private network between enabled devices. Products that use GopherInsight™ can have network access without using traditional Bluetooth, Cellular, or Satellite connectivity.

Earlier this week, GBT Technologies announced that GBT Tokenize, its JV, has concluded qTerm device's features, adding two features. qTerm, a human vitals device, powered by AI, is aimed to measure human vitals with a touch of a finger. In addition, the device also received its Trademark allowance notice and will present it on the product/package as required by the United State Patent Office (USPTO).

Yesterday, GBT Technologies announced that it received a notice of allowance for application number 16/292,388 that was filed on March 5, 2019, issued by the United States Patent and Trademark Office (USPTO) for its 3D, Monolithic, multi-dimensional, multi-plane, memory structure for integrated circuits patent. This application was examined by the USPTO and is allowed for issuance as a patent. GBT expects that it will receive a granted date during the next few months.

GBT Technologies, Inc. (GTCH), closed Friday's trading session at $0.0115, off by 4.1667%, on 659,704 volume with 39 trades. The average volume for the last 3 months is 1,361,984 and the stock's 52-week low/high is $0.0087/$2.03999996.

Muscle Maker, Inc. (GRIL)

ChartMill, Zacks, The Stock Market Watch, MarketWatch, Investing Note, Investing.com, Market Screener, Webull, Finviz, QSRMagazine.com, TradingView, Nasdaq, GuruFocus, GlobeNewswire, Stockhouse, Investors Observer, Seeking Alpha, MarketBeat, MacroTrends, Barchart, Stocknews, Invest Million, Business Insider, Restaurant Business Online, Simply Wall St, Morningstar, InvestorsHub, Franchising.com, DBT News, Wallet Investor, and Stock Analysis reported beforehand on Muscle Maker, Inc. (GRIL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Muscle Maker, Inc. is the parent company of Muscle Maker Grill, Healthy Joe’s, and MMG Burger Bar, a fast-casual concept known for serving “healthier for you” meals. Muscle Maker Grill features high quality, appetizing food, freshly prepared with proprietary recipes. The Company provides its guests healthier versions of mainstream-favorite dishes that are flavorful. Its emphasis is making it easy, affordable, as well as enjoyable for its guests to eat healthy. Muscle Maker Grill was established in 1995 in Colonia, New Jersey. The Company lists on the Nasdaq Global Select Market. Muscle Maker has its head office in Burleson, Texas.

Muscle Maker’s menu was created with guests’ health in mind. The menu is lean and protein based. It features all-natural chicken, grass fed steak, lean turkey, whole wheat pasta, wraps, bowls, and more. Additionally, the menu offers a wide selection of fruit smoothies in a variety of assorted flavors, protein shakes, and supplements. Muscle Maker Grill’s menu also features options that satisfy an array of dietary preferences - from vegetarians to the low-carb consumer, and guests following a gluten-free diet.

Muscle Maker has started to open the first five, of the initial ten, ghost kitchens it had previously announced in the Chicago market. These five delivery-only ghost kitchens enable Muscle Maker to cover the whole Chicago market at a fraction of the cost it would take to build out traditional locations for the same geographical coverage. The Company continues to believe that this vertical can offer it substantial accretive growth from the initial ten location agreement while leveraging the continued delivery trend in the restaurant industry.

Pertaining to military locations, Muscle Maker opened Camp Elmore in Q2. Camp Elmore is a Marine base. It represents a third branch of the military with opportunities to bring healthier food options to the armed forces.

Muscle Maker has signed an agreement to open two more ghost kitchens in Philadelphia, Pennsylvania. Muscle Maker will now operate seven ghost kitchen facilities in two major cities across the U.S.

Earlier this week, Muscle Maker announced that it, along with one of its franchise partners, signed agreements to open three delivery only ghost kitchens throughout the U.S. The first delivery only ghost kitchen will be located in downtown Providence Rhode Island and will be operated by Muscle Maker, Inc.

The Company’s non-traditional growth model will now stretch from coast-to-coast with the openings of two ghost kitchens in two major metropolitan cities. The first will be in downtown San Francisco. The other will be in downtown San Jose. Both of these locations will be operated by a local franchisee who also owns and operates the Antioch, California location.

In addition, this week, Muscle Maker announced that it, along with its shareholders, elected Major General Malcolm Frost and finance professional Mr. Philip Balastos to its Board of Directors. The Company plans to take advantage of General Frost’s experience in negotiating with the military’s top brass to ensure opportunities are maximized and company military contracts are launched efficiently. Mr. Balastos has a tenured finance background. He will bring more than two decades of public markets experience to the Board of Directors.

Muscle Maker, Inc. (GRIL), closed Friday's trading session at $1.81, up 11.7284%, on 1,710,067 volume with 3,303 trades. The average volume for the last 3 months is 2,071,149 and the stock's 52-week low/high is $1.30999994/$5.09000015.

New Found Gold Corp. (NFGFF)

SmallCapPower, StocksCafe, Ahead of the Herd, The Hedgeless Horseman, The Prospector News, OTC Markets, Newswire.ca, Financhill, GlobeNewswire, Resource World, 321gold, Morningstar, FX Empire, TradingView, Fintel, Northern Miner, Mining Journal, Nasdaq, Seeking Alpha, Wallmine, Central Charts, Barchart, PR Newswire, News Break, KEreport.com, Market Screener, MarketWatch, Stockhouse, CEO.ca, GuruFocus, Dividend Investor, Wallet Investor, ValueTheMarkets, Investor Ideas, The Globe and Mail, Newsfilecorp, Stockwatch, Dividend.com, and MarketDepth reported earlier on New Found Gold Corp. (NFGFF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A mineral exploration company, New Found Gold Corp. engages in the identification, acquisition, and exploration of mineral properties in the Provinces of Newfoundland and Labrador and Ontario. It holds a 100 percent interest in the Queensway Project, positioned 15 km west of Gander, Newfoundland, and 18 km from Gander International Airport. The Company previously went by the name Palisade Resources Corp. It changed its name to New Found Gold Corp. in June of 2017. Established in 2016, New Found Gold is based in Vancouver, British Columbia. The Company lists on the OTC Markets.

The Queensway Project is intersected by the Trans-Canada Highway and has logging roads crosscutting the project, high voltage electric power lines running through the project area, and easy access to a highly skilled workforce. The Company has completed the largest ever consolidation of property within the Central Newfoundland Gold Belt. It controls the most advanced prospects along the Central Newfoundland Gold Belt. This includes 17 known high grade gold showings.

New Found Gold also has its Lucky Strike Project in Kirkland Lake, Ontario. It is 10,000 hectares in the heart of the Abitibi Greenstone Belt adjacent to the prolific Larder-Cadillac deformation zone. The Lucky Strike Project contains the past producing Walsh Mine and two exploration shafts at the Copper King and Norwood Kirkland. A number of splay fault structures of the Victoria Creek Deformation Zone cross the property with very limited exploration and open for significant new discoveries.

New Found Gold has working capital of roughly C$75 million. It is well financed for aggressive exploration with an initial planned drill program of 100,000 meters. The Company has a proven capital markets and mining team. Major shareholders include Palisades Goldcorp (33 percent), Mr. Eric Sprott (18 percent), Novo Resources (11 percent), Mr. Rob McEwen (7 percent), other institutional ownership (8 percent), and Management, Directors and Insiders (4 percent).

This week, New Found Gold announced preliminary results from the first four 2020 drill holes (NFGC-20-18, 19, 21, and 23) at the Keats Zone as part of a continuing 100,000 m diamond drill program at its 100 percent owned Queensway High-Grade Gold Project, 15 km west of Gander, Newfoundland.

Mr. Greg Matheson, P.Geo., Chief Operating Officer of New Found Gold, stated: "We are very pleased that our initial step-out drilling at Keats is demonstrating strong continuity of veining and high-grade gold mineralization. Our 10 m step out pattern around Hole NFGC-19-01 is providing valuable information about the orientation of veining and grade distribution. Historic work and more recent drilling at Keats have demonstrated gold mineralization over at least 300 m of strike and the target remains open along strike and to depth. Our program will continue systematic step out drilling to test this larger target area."

New Found Gold Corp. (NFGFF), closed Friday's trading session at $3.32932, up 21.508%, on 568,134 volume with 846 trades. The stock's 52-week low/high is $1.39999997/$3.40000009.

PolarityTE, Inc. (PTE)

Stocklight, Zacks, Stocktwits, Stock Analysis, MacroTrends, Seeking Alpha, Nasdaq, Investors Observer, Simply Wall St, Finviz, Stockhouse, ChartMill, Morningstar, InvestorsHub, TradingView, The Globe and Mail, Fintel, News Heater, TMX.com, Preferred Stock Channel, Wallet Investor, Businesswire, Barchart, Market Screener, DBT News, MarketWatch, Finbox, Wallmine, and MarketBeat reported earlier on PolarityTE, Inc. (PTE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

PolarityTE, Inc. concentrates on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. It is working to be the first company to truly deliver regenerative medicine into clinical practice. The Company uses a patient’s own cells and tissues to regenerate functionally-polarized human tissue. Incorporated in 1998, PolarityTE is based in Salt Lake City, Utah. The Company’s shares trade on the Nasdaq Capital Market (NasdaqCM).

PolarityTE is built on the principle that self must regenerate self. The Company manufactures products from the patient's own tissue and utilizes the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, PolarityTE creates an easily deployable, dynamic, as well as self-propagating product designed to regenerate the target tissues.

The intention of the Company’s unique methods are to promote and speed up growth of the patient's tissues to undergo a form of effective regenerative healing. PolarityTE’s SkinTE™ is an autologous skin construct. The intention of it is be used by physicians or other appropriate healthcare providers for the repair, replacement, reconstruction, or supplementation of skin tissue and integumentary system. Greater than 900 patients have been treated with SkinTE™.

Last month, PolarityTE announced it received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled, "Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds." The Phase I grant, which totals roughly $245,000, is funded over a six-month period. It will support research to apply for a subsequent larger Phase II grant.

PolarityTE will report calendar Q3 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time (ET). Furthermore, the Company will host a conference call and webcast with Q&A on November 9, 2020 at 8:00 a.m. ET.

PolarityTE, Inc. (PTE), closed Friday's trading session at $0.989, off by 0.070729%, on 395,509 volume with 882 trades. The average volume for the last 3 months is 512,173 and the stock's 52-week low/high is $0.779999971/$4.5999999.

Qualstar Corporation (QBAK)

Zacks, OTC Markets, Stock Analysis, QuantumOnline, Netcials, Wallet Investor, Stocknews, News Quantified, The Globe and Mail, Street Insider, Investors Observer, Business Insider, Barchart, Fintel, Seeking Alpha, GuruFocus, Stockhouse, Businesswire, Stocktwits, last10k, Finbox, MarketWatch, Investing.com, Simply Wall St, Market Screener, InvestorsHub, and MarketBeat reported earlier on Qualstar Corporation (QBAK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Qualstar Corporation is a foremost manufacturer of data storage solutions and high-efficiency power supplies. The Company offers a full range of tape libraries in different sizes and configurations to meet any requirements. Its data storage products provide highly scalable and reliable solutions to store and retrieve very large quantities of electronic data. Qualstar has its corporate headquarters in Camarillo, California. The Company lists on the OTC Markets.

Qualstar was established in California in 1984 for the development and manufacture of digital storage solutions. By 1995, it had focused its efforts on magnetic tape libraries used to store, retrieve, and manage digital data. The Company offers leading-edge tape storage solutions, with energy efficient libraries that employ the latest LTO tape drive technology and ultradense cartridges.

Qualstar is one of the few remaining fully independent tape library manufacturers. The Company has 36 years of experience and expertise delivering data storage solutions. It has an international footprint with strategic presences in the USA, South Korea, China, and Germany.

Qualstar has vertically integrated in-house capabilities and ISO, RoHS, UL, as well as FCC certified products. In addition, it has expert technical support on call to help customers through any issue. Furthermore, it has no slot licensing fees. Moreover, scalable libraries easily grow with business requirements. This is from entry-level to enterprise-class.

Qualstar is developing solutions specific to a number of the vertical markets to which its customers belong. These markets include Media & Entertainment; Oil & Gas; Government & Military; Education; and Information Technology (IT). Additionally, these markets include Medical Imaging; Banking; Surveillance; as well as Data Centers for Cloud Services.

In July of 2002, Qualstar purchased the assets of N2Power, Inc. N2Power is a supplier of ultrasmall, high-efficiency open-frame power supplies. These switching-mode power supplies sell under the N2Power brand name and to OEMs (Original Equipment Manufacturers) by way of private-label brand names. In 2014, Qualstar created a Singapore corporation as part of its plan to grow its engineering and product development staff so as to support its overall product expansion. Qualstar also offers data storage systems marketed under the Qualstar™ brand.

Qualstar Corporation (QBAK), closed Friday's trading session at $2.45, off by 2.7778%, on 2,335 volume with 9 trades. The average volume for the last 3 months is 1,618 and the stock's 52-week low/high is $1.65999996/$6.50.

Tremor International Ltd. (TTTPF)

OTC Markets, StocksCafe, TradingView, Dividend.com, Market Screener, Seeking Alpha, Wallet Investor, Dividend Investor, YCharts, Macroaxis, Stock Target Advisor, Market Wire News, Barchart, Morningstar, Trade Ideas, Fintel, FX Empire, The Online Investor, MarketBeat, wallstreet-online, Ask Finny, Stockhouse, GuruFocus, MarketWatch, and Nasdaq reported earlier on Tremor International Ltd. (TTTPF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Tremor International Ltd. is an international leader in video advertising technologies. The Company has three core divisions. These are Tremor Video, RhythmOne, and Unruly. In essence, the Company offers digital advertising solutions that take advantage of the latest video, native, and display technology to reach the most valuable users for every app, service, and brand.

Tremor International lists on the OTC Markets. Established in 2007, the Company has its corporate head office in Israel. In addition, Tremor maintains offices throughout the United States and Canada, Asia-Pacific, Europe, India, and also Latin America. The Company previously went by the name Taptica International Ltd. It changed its name to Tremor International Ltd. in June of 2019.

Tremor International has operations in more than 60 countries. The Company works with greater than 450 advertisers. These include Amazon, Disney, Twitter, OpenTable, Expedia, and Zynga. Furthermore, Tremor International works with more than 50,000 supply and publishing partners around the world.

The Tremor Video division helps advertisers deliver impactful brand stories across all screens via the power of unique video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America. It has offerings in CTV, instream, as well as in-app.

The RhythmOne division drives real business outcomes in multiscreen advertising. Its highly ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-centered clients and partners.

The Unruly division is a data-driven marketplace. It has greater than 2,000 direct integrations with publishers, innovative demand relationships with the world's largest advertisers, and privileged access to News Corp inventory.

Unruly works with 95 percent of the AdAge 100. Moreover, 82 percent of video views are delivered across Comscore 1,000 sites. Publishers use Unruly’s international relationships with premium demand partners, reader-friendly ad formats, self-serve tools, and dedicated support team to maximize their revenue across a range of different screens, including CTV, mobile, and desktop.

Tremor International Ltd. (TTTPF), closed Friday's trading session at $2.86, up 78.75%, on 20,544 volume with 11 trades. The average volume for the last 3 months is 2,434 and the stock's 52-week low/high is $0.001099999/$2.71740007.

Minerco, Inc. (MINE)

TipRanks, Investing.com, Streetwise Reports, Global Banking and Finance, Market Wire News, Metals News, Wallet Investor, Dividend Investor, Infront Analytics, TradingView, Nasdaq, Market Screener, GlobeNewswire, PR Newswire, InvestorsHub, Stockwatch, Stockopedia, Investors Hangout, and Stockhouse reported earlier on Minerco, Inc. (MINE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Minerco, Inc. is a brand management business specializing in the development of beverage, entertainment, and also ancillary brands. The present Minerco beverage brand umbrella includes VitaminFIZZ® and The Herbal Collection™. The Company was previously known as Minerco Resources, Inc. It changed its name to Minerco, Inc. in October of 2015. Its shares trade on the OTC Markets. Minerco has its corporate headquarters in Katy, Texas.

Minerco’s entertainment company is Fuse Live Events. It supplements the Company’s portfolio via the generation, production, and promotion of premier quality live entertainment. These include concerts, festivals as well as other live events.

Minerco’s new management is concentrating on entertainment and media assets. This is in addition to enhancing the Company’s proprietary beverage formulas with added functionality, to include CBD (cannabidiol).

Recently, Minerco and Anything Technologies Media, Inc. (EXMT) announced that the companies signed a joint venture (JV) agreement to develop, market, and distribute a new line of CBD products. The JV will take advantage of Minerco’s proven beverage formulations and distribution with Anything Technologies Media’s (ATM’s) hemp/CBD expertise to jointly and efficiently take the new line of products to the marketplace. ATM is a manufacturer and developer of CBD products.

The initial product to undergo development and launching will be a zero calorie, vitamin packed CBD water. Upon initial CBD water development being complete, the JV’s plan is to quickly add coffee-based CBD and other products to the portfolio.

Mr. Milton Murcia, Minerco’s Chief Executive Officer, said, "We are very pleased to have partnered with ATM in this joint venture. The combined yet specialized expertise of both companies is exactly what we have been looking for. Both companies have the vision, resources and knowledge to create superior CBD products that will benefit the millions of people who want and need them. This is just the start to our vision of being a leader in the development and distribution of health conscience CBD products.”

Minerco, Inc. (MINE), closed Friday's trading session at $0.0001, up 100.00%, on 14,292,800 volume with 370 trades. The average volume for the last 3 months is 5,955,957 and the stock's 52-week low/high is $0.000000999/$0.001.

CLIC Technology, Inc. (CLCI)

Investing News, Stockhouse, Street Insider, Stockwatch, Stock of the Week, Make Penny Stocks Great Again, OTC Market Research, GuruFocus, PennyStocks.News, BlockChainWire, InvestorsHub, and Simply Wall St reported previously on CLIC Technology, Inc. (CLCI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A "Financial Technology" company, CLIC Technology, Inc. is the developer and marketer of new, pioneering blockchain products and services. It has created an innovative "crypto-payment gateway system." This system enables consumers to use cryptocurrency to make routine purchases online. The system enables merchants to accept crypto payments and receive immediate settlements in traditional fiat currencies.

CLIC Technology has its head office in Aventura, Florida. The Company lists on the OTC Markets. Market introduction of the new crypto-payment gateway system and related services is planned to take place in a phased rollout in the United States and other major markets in the coming months.

CLIC Technology is lending its services to the developing cannabis and CBD (cannabidiol) industries. The Company is joining forces with Chicago’s LeafyQuick CBD Delivery Service. LeafyQuick has opted to register for CLIC’s ClicPay online payment gateway pilot program, a cutting-edge cryptocurrency platform for merchants that will accept blockchain payments and convert them into local currency securely, all within 24 hours.

This program is a step towards the future for companies such as LeafyQuick. It permits them to sidestep burdensome regulations imposed by payment processors over an industry that experts predict will soon be worth upwards of $20 billion. The ClicPay Merchant Gateway will offer LeafyQuick and others like them a fast setup with simple integration. This is an option that gives the whole CBD industry the capability to start accepting cryptocurrency payments instantly.

CLIC Technology Chief Executive Officer, Roman Bond, said, “We are extremely excited to be working with LeafyQuick, and to be able to help move the CBD industry forward. Turning cryptocurrency into everyday fiat is going to be a game-changer for many in the industry.”

CLIC Technology, in collaboration with blockchain infrastructure provider and B2B platform Opporty, is ready to launch a progressive browser extension that will revolutionize the e-commerce industry. It will allow consumers to make everyday purchases on Amazon using the open source, public, blockchain-based distributed computing platform Ethereum.

Powered by Plasma Cash design pattern for off-chain processing of an on-chain assets provided by Opporty, the new extension will bring a modern day cryptocurrency economy one step closer to becoming a reality. The two companies plan to create payment platforms processing Ethereum, as well as any tokens based on ERC-20, ERC-721, and other Ethereum compatible standards. This will open up a host of possibilities for consumers to use digital currency in the e-commerce marketplace.

CLIC Technology, Inc. (CLCI), closed Friday's trading session at $0.05, up 92.3077%, on 3,466 volume with 4 trades. The average volume for the last 3 months is 9,451 and the stock's 52-week low/high is $0.004999999/$0.119999997.

Invictus MD Strategies Corp. (IVITF)

NetworkNewsWire, Tip Ranks, The Street, Dividend Investor, GuruFocus, Pot Network, Emerging Growth, Profit Confidential, Insider Financial, Penny Stock Tweets, Stockhouse, Market Screener, OTC Markets, Investing News, YCharts, Daily Marijuana Observer, CapitalCube, Barchart, Equities, Financial Content, Midas Letter, InvestorsHub, Wallet Investor, and MarketWatch reported earlier on Invictus MD Strategies Corp. (IVITF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Invictus MD Strategies Corp. is a global cannabis company based in White Rock, British Columbia. Invictus offers a selection of products under a wide range of lifestyle brands. The Company and its subsidiaries primarily engage in the investment, acquisition, and development of synergistic businesses in the medical cannabis industry in Canada. Invictus MD Strategies lists on OTC Markets’ OTCQX.

Invictus’ commitment is to providing patients and adult users with high-quality medical-grade cannabis. It represents a strong platform of licensed cannabis producers across Canada. The Company has secured one of the strongest cultivation profiles in Canada, supported by more than 250 acres of production capacity. Through more than 50,000 kgs by 2021. Invictus supports its growers with state-of-the-art production and processing facilities.

Invictus MD Strategies’ portfolio includes Acreage Pharms Ltd. (West-Central Alberta – 100 percent Ownership); AB Laboratories, Inc. (Hamilton, Ontario – 50 percent Ownership); and AB Ventures, Inc. (Hamilton, Ontario - 33.3 percent Ownership). In addition, its portfolio includes Future Harvest (Kelowna, British Columbia - 82.5 percent Ownership).

Recently, Invictus announced that it entered into a non-binding Letter of Intent (LOI) with GTEC Holdings Ltd. for the acquisition by Invictus of all of the issued and outstanding shares in the capital of GTEC in an all-share transaction valued at roughly $100 million, forming Western Canada's largest indoor vertically integrated cannabis companies. The combined entities would provide a vertically integrated cannabis company, centered on producing premium flower and complementary product portfolio, cultivated in purpose-built indoor facilities complemented with first-class genetics.

Mr. George E. Kveton, Invictus MD Strategies’ Chief Executive Officer, said, "We have been pleased with the continued execution of the team and business strategy at GTEC. The dedication to producing a premium product medical and adult-use recreational portfolio for the industry has always been our relentless pursuit. This merger allows for both companies to leverage the combined core competencies to further execute our vision to be at the forefront of the Canadian cannabis industry and beyond."

Invictus MD Strategies Corp. (IVITF), closed Friday's trading session at $0.022, up 80.3279%, on 363,479 volume with 39 trades. The average volume for the last 3 months is 118,518 and the stock's 52-week low/high is $0.000099999/$0.146599993.

AdvanSource Biomaterials Corp.  (ASNB)

TopPennyStockMovers, Zacks, Money Morning,  S.A. Advisory, Marketbeat, Penny Stock Tweets, and Nebula Stocks reported on AdvanSource Biomaterials Corp. (ASNB), and we also report on the Company, here at the QualityStocks Daily Newsletter. 

AdvanSource Biomaterials Corp. is an ISO certified materials technology company headquartered in Wilmington, Massachusetts.  Specialists in polyurethane technologies, the Company provides a variety of material formats for use in long and short-term implants and disposable products.  Fundamentally, AdvanSource is a foremost developer of advanced polymer materials for a wide spectrum of medical devices.

AdvanSource Biomaterials lists on the OTC Markets’ OTCQB.  The Company formerly went by the name CardioTech International, Inc. It changed its name to AdvanSource Biomaterials Corp. in October of 2008.

The Company serves the medical device and pharmaceutical market. AdvanSource’s materials have a history of use in short and long-term implant applications. These include stents, artificial heart valves, VADs, catheters, guidewires, and introducers. 

AdvanSource Biomaterials’ expertise lies in the synthesis and formulation of polymeric materials with a broad array of physical and chemical properties. These materials possess innovative characteristics including biocompatibility and biodurability. They can be tailored for specific properties, including lubricity and antimicrobial formats.

The Company’s biomaterials are used in devices designed for treating a wide spectrum of anatomical sites and disease states.  Products include ChronoFlex AL; ChronoFlex AR; ChronoFlex C; ChronoPrene; ChronoSil; ChronoThane P; ChronoThane T; HydroMed; HydroThane; and PolyBlend.

ChronoFlex AL is a family of biodurable aliphatic polycarbonate-based thermoplastic urethanes. The design of these is to overcome surface degradation such as stress-induced microfissures.   

PolyBlend is a family of very soft, aromatic polyurethane elastomeric alloys. These can be used as a substitute for natural rubber or latex in many applications. HydroMed is a series of ether-based hydrophilic urethanes with premier adhesive and cohesive properties.

Markets AdvanSource Biomaterials serves include orthopedics, cardiovascular, drug delivery, endoscopy, neurology, urology, spine, interventional radiology, peripheral vascular, ENT, gastroenterology, oncology, and diabetes management.

The Company has a strategic alliance with Medibrane Ltd. Medibrane is a top Israeli coating technology company. The Strategic Alliance provides for technology collaboration, development, and commercialization of medical coatings utilizing AdvanSource’s material technologies in collaboration with Medibrane’s coating and surface modification technologies and enhancements. Medibrane is a designer, developer and manufacturer of customized polymeric surgical implants, implantable device coatings, encapsulation coatings, as well as bio-absorbable implants.

AdvanSource Biomaterials Corp. (ASNB), closed Friday's trading session at $0.0365, up 73.8095%, on 15,028 volume with 3 trades. The average volume for the last 3 months is 22,633 and the stock's 52-week low/high is $0.015599999/$0.230000004.

Vilacto Bio,  Inc. (VIBI)

OTC Markets and The Street reported on Vilacto Bio,  Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vilacto Bio,  Inc.  is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In numerous studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present the Company’s products are available on the market as Vilact®.

Founded in 2013, Vilacto Bio is headquartered in New York, New York. The Company previously went by the name Zlato, Inc. It changed its name to Vilacto Bio, Inc. on April 4, 2017. The Company’s European Headquarters are in Næstved, Denmark. Its Research and Development (R&D) operations are in Lithuania.

Vilacto Bio’s goal is to be the leading biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties.  The Company’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, as well as licensing out its Lactoactive® molecule for the pharmaceutical industry.

Lactoactive® is highly refined colostrum, developed to provide first-rate results for people needing healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin. 

Vilacto Bio has its Vilact Cuticle cream product, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with faster patient recovery.

This past January, Vilacto Bio announced that it started development of the Vilacto Bio Skincare Knowledge Center. This is an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.

The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines internationally, and also with Vilacto customers. The expectation is that the Vilacto Bio Knowledge Center will enhance dialogue among specialists and consumers, improve outcomes, and drive higher traffic to Vilacto Bio’s commercial web portal.

Vilacto Bio,  Inc. (VIBI), closed Friday's trading session at $0.0002, up 100.00%, on 1,383,352 volume with 5 trades. The average volume for the last 3 months is 8,573,504 and the stock's 52-week low/high is $0.000000999/$0.000199999.

Foothills Exploration, Inc. (FTXP)

MarketWired, OTC Markets, and InvestorsHub reported on Foothills Exploration, Inc. (FTXP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Foothills Exploration, Inc., through its wholly-owned subsidiary, Foothills Petroleum, Inc. (a Nevada corporation), is an early stage independent oil and gas exploration and production company. It involves in the acquisition and development of oil and gas properties in the Rockies. The Company’s goal is to acquire dislocated and underdeveloped oil and gas assets and maximize those assets. Foothills Exploration is headquartered in Denver, Colorado.

The Company’s strategy is to build a balanced portfolio of E&P assets through concentrating on acquiring producing and developmental properties in the Rockies and focusing on the generation of high-impact oil and gas exploration projects. Foothills Exploration’s goal is to build a land bank of more than 200,000 acres of proven, probable, and prospective reserves.

Currently, Foothills Exploration holds 41,181 acres in the Greater Green River Basin in Wyoming. Its Springs Prospect consists of 38,120 contiguous acres. This is a multiple objective oil resource play in the Greater Green River Basin.

Moreover, the Company has a 35 percent Working Interest (WI) in the Ladysmith Anticline prospect. This prospect is in Fremont County, Wyoming. Ladysmith Anticline in entirety amounts to 3,061 acres. Its location is between the Great Divide/Greater Green River Basin and the Wind River Basin.

Foothills also has its PawPaw Project. The Pawpaw project is a 3-D seismic defined prospect. It covers 4,467 acres and is a direct analog to the highly productive Tensleep Formation “Enigma” Field positioned two miles south.

The Company also has its Ironwood Project. The Ironwood Project is a 6,115-acre up dip field extension play. The adjacent “Cotton Creek” Field produced about 67 million barrels of oil (MMBO) and 68 billion cubic feet of gas (BCFG), chiefly from the Phosphoria Formation.

Foothills Exploration announced in February 2017 that since acquiring Tiger Energy Partners International on December 30, 2016, Foothills has successfully reworked two wells in its Duck Creek project obtaining production from the Green River formation.

Regarding the Duck Creek Area – Natural Buttes Field, Foothills Exploration plans to re-enter two wells in September in the Duck Creek region situated in Uintah County, Utah, in the Natural Buttes field. The Duck Creek wells recently had a third-party engineering report completed. The Report calculated a total PV-10 value of $707,000 of Proved Developed Producing and Proved Developed Non-Producing reserves.

Concerning the Altamont- Bluebell and Brundage Canyon areas, a third-party reserve report was conducted on certain properties, which were acquired via the Tiger Energy Partners International acquisition. According to this Report, the properties have roughly 5.4 million barrels of Proved Undeveloped Reserves. The well depths range from 5,500 feet in the Brundage Canyon area to roughly 18,000 feet in the Altamont-Bluebell area.

Foothills Exploration, Inc. (FTXP), closed Friday's trading session at $0.0006, up 50.00%, on 18,915,085 volume with 18 trades. The average volume for the last 3 months is 24,628,578 and the stock's 52-week low/high is $0.000099999/$0.046500001.

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), an innovative fintech solutions provider that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire, today announced that it has sold its remaining interest in the SRAX MD asset. “Our SEQUIRE platform is rapidly growing and we are focused on the continued expansion of this business. To view the full press release, visit http://ibn.fm/fsG9O

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $2.60, up 5.6911%, on 204,093 volume with 654 trades. The average volume for the last 3 months is 133,461 and the stock's 52-week low/high is $1.05/$3.357.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM) takes environmental stewardship seriously by providing environmentally beneficial solutions for storm waste disposal that transform landfill-bound trees into next-generation organic mulch products and certified playground surface material. Despite the global recession, the company continues to grow. Through its subsidiary Mulch Manufacturing Inc., SGTM has been awarded contracts to supply The Kroger Co. and Alimentation Couche-Tard Inc. - specifically, for three divisions of its Circle K subsidiary. Also today, the company was featured in a publication from InvestorWire, examining the announced completion of the company’s two-year 2018 and 2019 audit, to commence the form-10 process to become fully reporting and for future uplisting. In addition, SGTM announced that its wholly owned subsidiary Mulch Manufacturing Inc. will be supplying quality mulch products and services to 7-Eleven stores throughout the Midwest U.S. and western New York, slated to commence in 2021. To view the full press releases, visit http://ibn.fm/0zStX and http://ibn.fm/RjIvD

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Friday's trading session at $1.49, up 24.1667%, on 1,625 volume with 12 trades. The stock's 52-week low/high is $1.472/$20.0783996.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), previously Altum Resource Corp., is a mineral-exploration and resource-development company focused on identifying economically viable resource opportunities in the Americas. The company has gold assets in Northern Chile and Western Canada. This year has been an exciting year for the company as it has undergone a name change, tapped into new opportunities, acquired resources and laid plans for the future. Also today, the company was featured in a publication from MiningNewsWire, examining how ATUMF has closed an initial tranche of an over-subscribed non-brokered private placement as previously announced on October 16, 2020, (the "offering"). According to the update, the company issued 11,307,500 units, each at a price of $0.20, for gross proceeds of $2,261,500.00. To view the full press release, visit http://ibn.fm/CxNp8

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Friday's trading session at $0.3172, up 24.4898%, on 204,800 volume with 24 trades. The stock's 52-week low/high is $3.40000009/$18.00.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF).

InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF), an innovative insurtech leader, has extended its general liability coverage to a vital sector of the U.S. economy—small businesses—with the launch of its business owner policy (“BOP”) portal. InsureThePeople.com enables small business owners and operators of a wide range of enterprises to purchase insurance protection, underwritten by Crum & Forster, for a variety of special needs. To view the full article, visit https://ibn.fm/VjF4K

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (OTC: IGSTF), closed Friday's trading session at $0.0897, even for the day, on 75,000 volume. The average volume for the last 3 months is 483 and the stock's 52-week low/high is $1.25820004/$5.68989992.

Recent News

Grey Cloak Tech Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech Inc. (GRCK).

Grey Cloak Tech (OTC: GRCK) (soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary development of natural plant-based formulations and sales and distribution of cardiovascular and neuro products, today announced the filing of its Form 10-Q for the third quarter ended Sept. 30, 2020. To view the full press release, visit http://ibn.fm/1y6zl

Grey Cloak Tech Inc. (GRCK), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology.

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit™ heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit™ in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.bergametna.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit™ supplements:

  • Support healthy immune systems with powerful antioxidants and proprietary formulations.
  • Reduce cholesterol and support healthy glucose and blood pressure levels.
  • Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free.
  • Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors.
  • Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation.

Ultimate Brain Nutrients

Grey Cloak’s Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS® proprietary formulations — targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents — one issued and four pending — targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (FDA) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Grey Cloak Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

  • Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
  • Unique management skills led to the development of successful teams for 35 years
  • Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
  • Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
  • Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
  • Specialized in customer relationship management (CRM) tools for creating the best customer experiences
  • Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

  • 35 years of diverse experience in corporate finance, insurance and accounting
  • 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
  • Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
  • Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
  • Involved in 30+ companies transitioning from private to public identities
  • Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

  • More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
  • Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
  • Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

  • Clinical professor of surgery at the University of Colorado, School of Medicine
  • Actively involved in medical research and clinical trials for 35 years
  • Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
  • Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
  • Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
  • Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
  • Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

Grey Cloak Tech Inc. (GRCK), closed Friday's trading session at $0.0608, up 10.5455%, on 4,135 volume with 1 trade. The average volume for the last 3 months is 17,372 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Rritual Mushrooms Inc.

The QualityStocks Daily Newsletter would like to spotlight Rritual Mushrooms Inc..

Rritual, a plant-based consumer wellness brand, was selected as runner up for the Buyers Choice Award at last week’s virtual ECRM program. According to an article on Business Wire, Rritual’s Reishi Relax Elixir was selected for the award among dozens of entries evaluated by retail buyers. To view the full article, visit https://ibn.fm/8aRmo

Rritual Mushrooms Inc. is a private company founded in 2019, whose declared purpose is to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets.

The company manufactures premium plant-based products such as small-batch elixir powders, and each product features mindfully selected medicinal mushrooms and adaptogenic herbs. Pursuing customers with various need-states, Rritual offers products that fit every lifestyle.

Suite of Premium Rritual(TM) Products

Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.

The initial product line includes:

  • Chaga (immune booster) – Full of bioactive polysaccharides, Rritual’s Chaga blend combines the Chaga mushroom with Eleuthero root for optimal immune system benefits.
  • Lion’s Mane (brain booster) – Designed to support cognitive function and brain health, Lion’s Mane is paired with Rhodiola root. The elixir can also help the body manage stress.
  • Reishi (stress support) – Rich in polysaccharides, triterpenes, amino acids and fatty acids, the Reishi blend is infused with Ashwagandha root. This combination aims to help the body and mind fight anxiety, with long term effects that may improve quality of sleep for those with restless minds.

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Hart said in a news release.

Rritual CEO David Kerbel noted that the company is proud to bring together age-old mushroom consumption practices and data-backed research to create new formulas that meet the needs of modern consumers. “Whether to relieve stress, increase mental output or boost immunity, we want to be a trusted and effective component of a consumer’s daily health and wellness routine,” he added.

Rritual Timeline

According to its investor presentation, Rritual has already fulfilled most of the milestones it set for Q1 and Q2 2020 as part of its growth and development timeline. So far, the company has completed formulation R&D, product line development, test marketing, brand development, logistics partnerships and agreements, initial distributor partnerships, seed financing and the phase one launch of its product suite.

Rritual E-Commerce Rollout Strategy

The company’s strategy for e-commerce rollout success consists of direct-to-consumer (D2C) sales through the use of multiple online platforms and through team connections to facilitate rapid expansion within the market.

In the first stage, Rritual will use its own website and Amazon to facilitate its D2C initiative, followed by leveraging its team connections to sell products through planned specialty e-commerce channels such as Costco, CVS, Walmart, and Vitacost using preexisting relationships.

Brick-and-Mortar Rollout Strategy

Using partnerships already in place with The Jet Collective and leveraging the preexisting connections of its team for direct discussions with global retail brands, Rritual’s brick-and-mortar strategy features a two-stage rollout that targets 15 leading retailers.

In the first stage, Rritual aims to launch with four non-competing chains, while utilizing best practice agreements (320 Sprouts stores, 330 H-E-B stores, 240 Meijer stores and 1,600 Publix stores). In stage 2, distribution is expected to advance to additional retail establishments (100 Wegmans stores, 77 Fresh Thyme stores, 440 Whole Foods stores, 120 Shaw’s stores, 400 Stop & Shop stores, 300 Wakefern/Shoprite stores, 610 Vitamin Shoppe stores, 90 Bartell Drug stores, 40 Giant Eagle market district stores and 1,800 Target stores), while collaboration with Kroger will take place within two sub-markets (300 Ralphs stores and 120 Harris Teeter stores).

Market Growth Outlook

As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth. At this time, no dominant brand is in place, and there remains an absence of a premium brand to lead the category.

The entire functional food market is currently valued at more than $275 billion, with global shifts supporting wellness and a 7.9% CAGR forecast through 2025. Demand for functional mushrooms is also growing, with a forecast rise from $23 billion to $34 billion by 2024 as a result of growing popularity due to the superfood’s unique properties that have been shown to boost immunity, cognitive function and more. The worldwide functional mushroom market is projected to exceed $50 billion by 2025, with recent data indicating an increase in demand for key mushroom varieties of up to 800%.

Management Team

David Kerbel, CPC, is CEO of Rritual and has over 30 years of senior experience in retail, brokerage and CPG industries. From 2008 to 2011, Kerbel served as Senior Vice President of Sales for Celsius Holdings Inc., helping that company achieve a number of important milestones. During his tenure, Celsius grew its retail sales from $400,000 to a multimillion-dollar figure, developed nationwide representation with CROSSMARK Inc. and established distribution with industry giants such as 7-Eleven, Ralph’s, C&S, Costco, BJ’s Wholesale, CVS, Walgreens, Walmart, Rite Aid, Target, Duane Reade and Stop & Shop. In total, Celsius’ new distribution stemming from Kerbel’s direct efforts led to $36 million in incremental sales in 2010 alone. He also implemented new procedures that led to a 10 percent reduction in operating expenses. Kerbel brings tremendous experience to the Rritual team, as well as vital relationships with industry leaders such as Walmart, Costco, Kroger, Walgreens, CVS, 7-Eleven, Safeway, Publix, Sprouts and more.

Warren Spence is the COO and a Director of Rritual. He has over 25 years in the food and beverage industry. His roles within the industry have included senior positions with brands like Red Bull and Olivieri. His specialization is in supply chain and operations systems. He was appointed Head of Supply Chain for Nude Beverages in 2019.

Dr. Mike Hart, MD, is the President of Rritual. His work has been published in peer-review journals about therapies involving cannabis and ketamine. His outspoken stance on these subjects landed him an appearance on the Joe Rogan Experience Podcast in 2019. On-air, he discussed the use of psychedelic medicines as a treatment for mental health conditions, including PTSD.

Stacie Gillespie is CCO and Director of Formulations for Rritual. She has over 25 years of leadership in the branding and product strategies used by wellness companies. She has leveraged this expertise for companies such as Aura Cacia, MegaFood and Gaia Herbs. She is the creator of multiple award-winning consumer health products.

Sarton Molnar-Fenton is Vice President of Sales-USA for Rritual. She started her career with Vitamin Water, with other large companies under her belt, including Danone, as a District Manager. She worked with Nestle on its Tribe Hummus brand and played an integral part in relaunching the brand, gaining category share and establishing product development partnerships with companies like Trader Joe’s. She also played a key role in launching the Hydralyte brand in the United States.

Scott Naccarrato is the company’s Vice President of Sales-Canada. He is experienced in sales with a deep connection in retail. Recently, he worked with Nutiva, assisting in the pioneering of Organic MCT oil, healthy fats and the plant-based protein categories. He is data-oriented in his approach, which has resulted in over $100 million in sales and double-digit year-over-year growth for the brands of which he has been a part.

Investment Considerations

  • Rritual’s suite of premium functional mushroom and adaptogenic elixirs is designed to offer various health benefits, such as increased immunity, cognitive function, stress management and more.
  • The company’s products are expected to be available online through Rritual’s site and Amazon by fall 2020.
  • The Rritual team has extensive ties and influential relationships with leading retail businesses, providing a wide market for growth.
  • The functional mushroom industry has no clear and dominant leader, allowing Rritual to target this role with its premium products. Rritual is currently the only premium brand on the market.
  • The global functional mushroom market is expected to exceed $50 billion by 2025, putting Rritual in the position for success.
  • Functional mushroom demand is expected to rise from $23 billion to $34 billion by 2024.

Recent News

chart

Pure Extracts Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Inc..

Pure Extracts, a private, plant-based extraction company, is leveraging growing acceptance by mainstream science and the general public to further develop and commercialize functional and medicinal mushroom products on a global scale. World-renowned mycologist Paul Stamets describes mushrooms as “nature’s miniature pharmaceutical factories” (https://ibn.fm/wbYSa). To view the full article, visit https://ibn.fm/qUzVJ

Pure Extracts Technologies Inc., headquartered in Pemberton, British Columbia, is a private, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extract is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.


Recent News

chart

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) was featured today in a publication from BioMedWire, examining how, for many living with heart and kidney diseases, taking care of their health includes managing their diets to suit medical recommendations that restrict the consumption of some nutrients. While this might be easy for some, a majority find it hard to follow these recommendations without tracking their nutrition through the day.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $1.6816, off by 6.0559%, on 28,217 volume with 142 trades. The average volume for the last 3 months is 88,593 and the stock's 52-week low/high is $1.258/$5.69.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how the COVID-19 pandemic has made it hard for companies to negotiate deals, as evidenced by the Freeport-McMoRan copper benchmark deal. Instead of personally receiving key customers during the London Metal Exchange Week, miners have resorted to using virtual meetings, whose progress is slower than traditional face-to-face meetings, to hammer out deals.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Friday's trading session at $1.51, off by 2.5806%, on 624,537 volume with 2,102 trades. The average volume for the last 3 months is 1,326,680 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) was featured today in the 420 with CNW by CannabisNewsWire. A global study that investigated the predisposition of individuals to cannabis use disorder has determined a link between a region of DNA near the FOXP2 gene and cannabis use disorder (“CUD”), previously associated with risk-taking behavior.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Friday's trading session at $1.25, off by 3.8462%, on 1,038,120 volume with 2,812 trades. The average volume for the last 3 months is 1,313,810 and the stock's 52-week low/high is $0.006/$1.09000003.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.”

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Friday's trading session at $0.7154, off by 5.006%, on 464,988 volume with 897 trades. The average volume for the last 3 months is 1,673,296 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining how a new study conducted by the University of New South Wales has discovered that right now is the most dangerous time for individuals with NCDs (noncommunicable diseases) such as cardiovascular conditions, respiratory problems, cancer and diabetes — primarily because of the COVID-19 pandemic.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday's trading session at $0.686, off by 4.5897%, on 276,160 volume with 509 trades. The average volume for the last 3 months is 1,232,020 and the stock's 52-week low/high is $0.67/$5.39.

Recent News

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF)

The QualityStocks Daily Newsletter would like to spotlight Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF).

Josemaria Resources Inc. (TSX: JOSE) (OMX: JOSE) ("Josemaria Resources" or the "Company") reports that, in accordance with the Swedish Financial Instruments Trading Act,  as a result of the issuance of common shares pursuant to the terms of previously announced credit facilities, the number of issued and outstanding shares of the Company has increased to 301,015,409 common shares with voting rights as at October 30, 2020 . View PDF Version

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF) is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project.

Josemaria Resources is part of The Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors all around the world.

The Josemaria Copper-Gold Project

The company’s flagship Josemaria Copper-Gold Project is located in the San Juan Province of Argentina – a well-known mining hub supporting a wide variety of mining service companies. The Lundin Group has been active in Argentina for approximately 30 years. Committed to advancing the project, Josemaria Resources has already begun the bridging phase, with basic and detailed engineering planning expected to commence in early 2021.

The company recently announced the results of a feasibility study at the Josemaria Project. The study, prepared by a team of engineering and consulting providers including Fluor Canada Ltd., SRK Consulting (Canada) Inc. and Knight Piésold Ltd., highlights a robust, low-risk project with rapid payback expected via an open pit operation with forecast capacity to feed a conventional process plant at a rate of 152,000 tonnes a day over a 19-year mine life.

According to the feasibility study, the project is expected to yield an average annual production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver. Other highlights of the study include:

  • The optimized mining production plan provides average grades in the first three years of production that are notably better than the life-of-mine average. This supports a forecast 3.8-year payback period from the start of production.
  • The project’s total initial cost, including engineering, procurement, construction, management, on- and off-site infrastructure, contingency and pre-construction engineering work, amounts to roughly $3.09 billion.
  • The location provides readily available access to essential resources, including water, grid power, transportation and logistics infrastructure within San Juan Province.
  • An Environmental and Social Impact Assessment (ESIA) of the project is already underway and is expected to be submitted to relevant authority agencies for review during Q1 2021.

The Josemaria Copper-Gold Project has been designed to incorporate the latest technology. Per the feasibility study, the project will include the use of autonomous trucks and production drill fleets, with the option of incorporating green energy, indicating the company’s commitment to minimizing and mitigating the adverse effects of mining on the environment.

To this end, the company intends to leverage suitable planning, impact assessment and monitoring tools while also incorporating water and energy efficiency systems and ecosystem conservation services in the design and implementation of its operations.

Josemaria Resources President and CEO Adam Lundin welcomed the results of the study as confirming that this is one of the very few readily developable copper-gold projects in the world and forecasting an attractive economic outcome for the asset, comparable with other copper-gold projects in development.

“We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction,” Lundin said in a news release.

Market Outlook

The global smart mining market was estimated at $6.8 billion in 2019. It is forecast to reach $20.31 billion by 2025. The significant increase is expected to be driven by technological advancements within the sector.

Global demand for copper is also growing steadily, due to the metal’s versatility and multiple uses for industrial, domestic and high-technology indications. The global copper market is expected to reach $222.1 billion by the end of 2026.

Management Team

Adam Lundin is the President, CEO and Director of Josemaria Resources. He has several years of experience in managing capital markets and public companies across the natural resources sector. His background includes oil, gas, mining technology, investment advising, international finances and executive management. Lundin began his career working for several of the Lundin Group mining companies. He is currently engaged in multiple roles, as he is also the Chairman for Filo Mining Corp. and Africa Energy Corp. and a Director of NGEx Minerals Ltd. and the Lundin Foundation.

Ian Gibbs serves as CFO of Josemaria Resources. He is a Canadian Chartered Accountant and a graduate of the University of Calgary, holding a Bachelor of Commerce degree. Gibbs has held many prominent positions within the Lundin Group of companies over the last 15 years, most recently as the CFO of Africa Oil Corp.

Arndt Brettschneider is the company’s Vice President of Projects. He has over 23 years of international mining, consulting and project development experience. Before joining Josemaria Resources, he was Vice President of the mining consulting businesses of two globally recognized engineering companies. Brettschneider obtained a Bachelor of Science with Honors from the University of Queensland in Brisbane, Australia. He received his MBA from Queen’s University in Ontario, Canada.

Bob Carmichael is the company’s Vice President of Exploration. He joined Josemaria Resources from Lundin Mining Corporation’s UK office. In his UK role, he was the General Manager of Resource Exploration. Carmichael is a registered Professional Engineer in the Canadian province of British Columbia. He obtained a Bachelor of Applied Science from the University of British Columbia. His dual role includes serving as Vice President of Exploration for Filo Mining Corp. and NGEx Minerals Ltd.

Alfredo Vitaller is Josemaria Resources’ General Manager in Argentina. He has been involved in the mining industry since 1993. He graduated as a Licentiate in Geological Sciences from Buenos Aires University and has an M.Sc. from Mackay School of Mines at the University of Reno. Vitaller has worked with the Lundin Group since 1993 and was a part of the exploration teams for Filo, Helados and Josemaria.

Notable Directors

Ashley Heppenstall, chairman of the Josemaria Resources board of directors, has over 30 years of experience in the oil and gas and resources sectors. From 2002 to 2015, Heppenstall served as the President, CEO and Finance Director of Lundin Petroleum AB, an oil and gas exploration and production company with core assets in Norway and Southeast Asia. He is credited with building Lundin Petroleum into the largest independent oil firm in the world today, leveraging a single equity raise of $50 million to guide Lundin in the design and implementation of a strategy that’s led it to a current market cap of roughly $6 billion.

Ron Hochstein has worked for the Lundin family directly as a consultant for over 20 years and is currently the President and CEO of Lundin Gold, a gold-producing business whose key asset is the Fruta del Norte gold deposit in Ecuador. Hochstein led construction efforts on the first mine in Ecuador, which went into production in 2019 and was completed on time and on budget.

Paul Conibear has been with The Lundin Group for over two decades, including serving as the CEO and Director of Lundin Mining from 2011 through 2018. Lundin Mining’s current market cap is estimated at $3.5 billion. In total, Conibear has more than 35 years of experience in progressively more responsible positions in the resource sector ranging through management of all phases of mine investment, including exploration, economic assessments, construction, operations and closure.

Josemaria Resources Inc. (OTC: JOSMF), closed Friday's trading session at $0.468, off by 3.243%, on 20,903 volume with 25 trades. The average volume for the last 3 months is 28,482 and the stock's 52-week low/high is $0.221/$1.74.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD) was featured today in the 420 with CNW by CannabisNewsWire. Although the state of Massachusetts allows the delivery of both medical and recreational marijuana, creating a system for delivering adult-use marijuana has proven to be quite a challenge. Recently, state marijuana regulators announced that they will be moving forward with plans to allow a new class of cannabis delivery business. The move has been met with both praise and criticism from stakeholders.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Friday's trading session at $0.0015, off by 6.25%, on 24,308,514 volume with 98 trades. The average volume for the last 3 months is 39,913,418 and the stock's 52-week low/high is $3.06999993/$14.3999996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.